<SEC-DOCUMENT>0001040130-23-000015.txt : 20230208
<SEC-HEADER>0001040130-23-000015.hdr.sgml : 20230208
<ACCEPTANCE-DATETIME>20230207175719
ACCESSION NUMBER:		0001040130-23-000015
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230206
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230208
DATE AS OF CHANGE:		20230207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PETMED EXPRESS INC
		CENTRAL INDEX KEY:			0001040130
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				650680967
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-28827
		FILM NUMBER:		23596396

	BUSINESS ADDRESS:	
		STREET 1:		420 SOUTH CONGRESS AVENUE
		CITY:			DELRAY BEACH
		STATE:			FL
		ZIP:			33445
		BUSINESS PHONE:		(561) 426-4444

	MAIL ADDRESS:	
		STREET 1:		420 SOUTH CONGRESS AVENUE
		CITY:			DELRAY BEACH
		STATE:			FL
		ZIP:			33445
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pets-20230206.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:f71bd024-2379-44df-bea2-c74ac69705bb,g:b581da7e-e97f-40a0-a46a-3202eaa8a288,d:d2f6d8fd7e924e0ab0b06303ecd9c763--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pets-20230206</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M180L2ZyYWc6M2ZiMjMxZTUwMzI2NDMxMzkyNWFjNGQ1YjY3ZDhmZDUvdGFibGU6MmI4ZmNlMjYzOTIxNDUwY2JjMDI0NzFiMjk5YjFjNzkvdGFibGVyYW5nZToyYjhmY2UyNjM5MjE0NTBjYmMwMjQ3MWIyOTliMWM3OV8xLTEtMS0xLTI0NjQw_3f88cd89-6b0e-4a79-a891-23f0811012bc">0001040130</ix:nonNumeric><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M180L2ZyYWc6M2ZiMjMxZTUwMzI2NDMxMzkyNWFjNGQ1YjY3ZDhmZDUvdGFibGU6MmI4ZmNlMjYzOTIxNDUwY2JjMDI0NzFiMjk5YjFjNzkvdGFibGVyYW5nZToyYjhmY2UyNjM5MjE0NTBjYmMwMjQ3MWIyOTliMWM3OV8yLTEtMS0xLTI0NjQw_3a5d8b54-b2b2-4b4a-a87e-8ca6d783ae7a">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pets-20230206.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001040130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-13</xbrli:startDate><xbrli:endDate>2023-01-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id2f6d8fd7e924e0ab0b06303ecd9c763_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzY5_b6d8efd9-0e66-4f33-b77e-48a723d33cd8">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzcw_5c83e5fe-2843-4d59-ad80-33e92443bbac">February 6, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzY2_bebc7565-abc5-4463-9def-94d0ab7d0df8">PetMed Express, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6YjQ1NTdlOGU4OTc0NDgxMGE5Y2JlZTU5YmQzNTEwNTQvdGFibGVyYW5nZTpiNDU1N2U4ZTg5NzQ0ODEwYTljYmVlNTliZDM1MTA1NF8wLTAtMS0xLTI0NjQw_0a5c9bcb-75e7-47a7-8b9c-912f16ddffc1">Florida</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6YjQ1NTdlOGU4OTc0NDgxMGE5Y2JlZTU5YmQzNTEwNTQvdGFibGVyYW5nZTpiNDU1N2U4ZTg5NzQ0ODEwYTljYmVlNTliZDM1MTA1NF8wLTItMS0xLTI0NjQw_66e74876-cd15-496f-b8e1-7f58bdf30b69">000-28827</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6YjQ1NTdlOGU4OTc0NDgxMGE5Y2JlZTU5YmQzNTEwNTQvdGFibGVyYW5nZTpiNDU1N2U4ZTg5NzQ0ODEwYTljYmVlNTliZDM1MTA1NF8wLTQtMS0xLTI0NjQw_d008f019-6ac7-4bf7-b250-f39b175fad40">65-0680967</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzYx_431e0d2e-3d83-40d8-b2b3-e380e1043410">420 South Congress Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzcx_9a21f683-8e90-4885-be29-a872f7716162">Delray Beach</ix:nonNumeric>, <ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzYy_84bc0e09-defb-4f5d-a223-36ad1f4540cd">Florida</ix:nonNumeric> <ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzY4_4490f66c-c6c6-4cd1-bb70-84c76c80f2d9">33445</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV80Mjc_b969d61d-a84c-4be6-944c-b71ca8e54c44">561</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzYz_27a45da4-004d-48ef-a6e7-66ea17d1fcb2">526-4444</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6NjVmMjA0MDM4MWY2NGI2MWFkZmJmNWMzYjlhMDk4NGIvdGFibGVyYW5nZTo2NWYyMDQwMzgxZjY0YjYxYWRmYmY1YzNiOWEwOTg0Yl8wLTAtMS0xLTI0NjQw_8b25a460-b9a5-4947-bce9-7552e3b3973d">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6NjVmMjA0MDM4MWY2NGI2MWFkZmJmNWMzYjlhMDk4NGIvdGFibGVyYW5nZTo2NWYyMDQwMzgxZjY0YjYxYWRmYmY1YzNiOWEwOTg0Yl8yLTAtMS0xLTI0NjQw_66b2c027-3cd3-4c39-ba4c-88caac8551b1">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6NjVmMjA0MDM4MWY2NGI2MWFkZmJmNWMzYjlhMDk4NGIvdGFibGVyYW5nZTo2NWYyMDQwMzgxZjY0YjYxYWRmYmY1YzNiOWEwOTg0Yl80LTAtMS0xLTI0NjQw_89fa5783-bea3-45cc-8fd4-a7eb2dab08e2">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6NjVmMjA0MDM4MWY2NGI2MWFkZmJmNWMzYjlhMDk4NGIvdGFibGVyYW5nZTo2NWYyMDQwMzgxZjY0YjYxYWRmYmY1YzNiOWEwOTg0Yl82LTAtMS0xLTI0NjQw_181bdc72-68a4-40c7-8fa2-91a48c18264f">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6MDc1YzA3ZTEyMDdmNDRjZWI1NTkyN2QwZDk5N2RlMjUvdGFibGVyYW5nZTowNzVjMDdlMTIwN2Y0NGNlYjU1OTI3ZDBkOTk3ZGUyNV8xLTAtMS0xLTI0NjQw_fac3bb8c-22e5-4f2c-b238-40390331d47b">Common Stock, par value $.001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6MDc1YzA3ZTEyMDdmNDRjZWI1NTkyN2QwZDk5N2RlMjUvdGFibGVyYW5nZTowNzVjMDdlMTIwN2Y0NGNlYjU1OTI3ZDBkOTk3ZGUyNV8xLTEtMS0xLTI0NjQw_1aff08d7-29ac-4090-9d43-2eb3cc74b908">PETS</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6MDc1YzA3ZTEyMDdmNDRjZWI1NTkyN2QwZDk5N2RlMjUvdGFibGVyYW5nZTowNzVjMDdlMTIwN2Y0NGNlYjU1OTI3ZDBkOTk3ZGUyNV8xLTItMS0xLTI0NjQw_86d15b6f-bf00-432a-9950-38450a6829e6">NASDAQ</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzY0_0ffec528-21ba-4e92-bfc1-ed77f5e0cdd2">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div></div><div id="id2f6d8fd7e924e0ab0b06303ecd9c763_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:0.08pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 6, 2023, PetMed Express, Inc. (the &#8220;Company&#8221;) held a conference call to discuss its financial results for the quarter ended on December 31, 2022. A copy of this conference call transcript is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-bottom:0.08pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:0.08pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information in this Item 2.02 and the information contained in Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such filing.</span></div><div style="margin-bottom:0.08pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="id2f6d8fd7e924e0ab0b06303ecd9c763_13"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(d)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-earningsconferenceca.htm">PetMed Express, Inc. conference call transcript dated February 6, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></div></td></tr></table></div><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K.  The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request by the SEC.</span></div><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*  *  *</span></div><div style="margin-bottom:0.08pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.08pt"><span><br/></span></div><div id="id2f6d8fd7e924e0ab0b06303ecd9c763_16"></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</span></div><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">               This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements.  Words such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;outlook,&#8221; &#8220;strategy,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;seek,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;strive,&#8221; &#8220;goal,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties, including: the risk that the Company may not be able to successfully complete the PetCareRx acquisition; the risk that the expected benefits to the Company from the acquisition will not be realized or will not be realized within the expected time periods; or unknown liabilities that may or may not be within the Company&#8217;s control. The Company&#8217;s future results may also be impacted by other risk factors listed from time to time in the Company&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2022, as well as other filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Current Report on Form 8-K and should not be relied upon as representing the Company&#8217;s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2</span></div></div></div><div id="id2f6d8fd7e924e0ab0b06303ecd9c763_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: February 7, 2023</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PETMED EXPRESS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">/s/ Christine Chambers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Christine Chambers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-earningsconferenceca.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if29d37aecb2f4d9f9f89f441677de90b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:109%">Exhibit 99.1</font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">PETMED EXPRESS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">QUARTER ENDED DECEMBER 31, 2022</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CONFERENCE CALL TRANSCRIPT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">FEBRUARY 6, 2023 AT 4&#58;30 P.M. ET</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Operator</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Good afternoon everyone and thank you for joining the PetMed Express Third Quarter Earnings Conference Call. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I would now like to pass the conference over to our host, Mr. Brian Prenoveau, Investor Relations. Sir, the floor is yours now.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brian Prenoveau</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thank you, Operator and I&#8217;d like to welcome everybody here today to the PetMed Express Fiscal Third Quarter Earnings Call.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information that will be included during this call may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934, as amended, that may involve a number of risks and uncertainties. These statements are based on our beliefs, as well as assumptions, we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual results could differ materially from those projected. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that any forward-looking results will occur or be realized, and nothing contained in this presentation is, or should be relied upon as, a representation or warranty as to any future matter, including any matter in respect to the operations or business or financial condition of PetMeds. PetMeds undertakes no obligation to update publicly these forward-looking statements based on subsequent events, except as may be required by applicable law, regulation, or other competent legal authority. We have identified various risk factors associated with our operations in our most recent Annual Report and other filings with the Securities and Exchange Commission.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, during the course of today&#8217;s call, the Company will be discussing one or more non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in the press release we issued this afternoon.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Now, let me introduce our CEO and President, Matt Hulett. Matt&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thank you, Brian.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thank you for making the time today to participate in our earnings call. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For anyone new to the PetMed Express company and story, PetMed is a company that delivers prescriptions and non-prescription medications, food, supplements, supplies and vet services direct to the consumer. Our expert online pharmacy is an established and trusted brand, as evidenced by the fact that we have served over 11 million pet parent customers over our Company&#8217;s 26-year operating history. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PetMeds is a leading pet retailer for both prescription and non-prescription medication. We have a loyal customer base of pet parents that value our brand, service, and quality. However, we believe our Company and this industry can be more to the millions of pet parents across the country, and our goal is to be the market leader in pet wellness and healthcare, or as we like to say, be the trusted pet health experts because we believe every pet deserves to live a long, happy, and healthy life.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be walking through the following components in today&#8217;s earnings call&#58; one, an update on our strategic roadmap, including our recent agreement to acquire PetCareRx&#59; two, a detailed review of our full year Q3 earnings&#59; and three, an overview of our go-forward thoughts related to our capital allocation strategy. From Management&#8217;s perspective, we are pleased with our results this quarter, as well as the progress we have made on the Company transformation. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Next slide, please. Over this last year, PetMeds has been in a rebuilding mode, with a new and experienced Management Team, an updated strategy, and a revised overall approach to the market as we transition to a growth-oriented business. I will provide an overview of our third quarter results, and then our CFO, Christine Chambers, will go into greater depth later in the presentation on our financial performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third quarter sales were $58.9 million compared to sales of $60.7 million for the same period the prior year. While this equates to a decrease in sales of 3% year-over-year compared to a double-digit decline in Fiscal Year 2022, one of the reasons that we are pleased with the quarter was that we saw an increase in net new customers of 9% year-over-year. This is an important milestone for the Company since we have not seen an increase in net new customers since Q1 of 2021. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most importantly, we achieved this while staying disciplined in terms of our customer acquisition efficiency metrics. Our new customer count for the quarter was approximately 72,000 compared to 66,000 in the prior year, and our LTV to CAC for the quarter was 1.6. Our average order value was $88, relatively flat to last year and last quarter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also saw continued growth in the recurring revenue side of our business. Our AutoShip and Save Program continues to grow and expand, and approximately 42% of our revenue was recurring revenue derived from our AutoShip Subscription Program during the second quarter. This part of our business increased 8% on a sequential basis and doubled year-over-year. AutoShip continues to be an important strategic lever for PetMed, especially considering that the focus of PetMeds&#8217; business has historically been solely focused on the prescription refills business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later in this presentation, we will walk through in detail our product catalog expansion strategy, especially as it relates to our agreement to acquire PetCareRx. We believe that there are clear expansion opportunities for more customer engagement in the non-medication space, which will increase our pet parent wallet share, generate more recurring revenues, and lead to an increase in customer lifetime value. Simply put, with a broader catalog assortment, we see an opportunity to attract new customers while selling more to our existing customers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have previously discussed what the Company strategy has been historically and what it will be going forward. PetMeds is shifting from being simply a leading pet medication retailer to being the pet health experts, a market leader in pet healthcare expertise. We want to be every pet parent&#8217;s go-to destination for holistic health and wellness, from nose to tail, and be that go-to destination over a pet&#8217;s entire lifecycle. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On that journey to becoming trusted pet health experts, we believe the strong relationships we&#8217;ve established with pet parents through pet medication prescriptions is an entryway to providing them with further goods and services, including prescription food, televet services, supplements, and soon, pet </font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance. The four points of our pawprint are medication, care, nutrition, and wellness. We view these points as being key to building a differentiated brand and experience to pet parents everywhere.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the shifts that are occurring in the regulatory landscape, which led us to our first big investment, pet telemedicine. Our investment in and partnership with Vetster enabled PetMeds to become what we believe to be the first pet retailer to offer pet telemedicine at scale. VetLive, our new co-branded offering with Vetster, connects pet parents to thousands of licensed veterinarians providing quality online vet services through video chat appointments 24&#47;7, and is exclusive to the PetMeds platform. We see the virtualization of vet services as being a key pillar of the pets business and a differentiator in the pet space. VetLive is a strategic advantage that will continue to develop as regulation changes and as consumer education and awareness develops.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pending acquisition of PetCareRx represents a significant opportunity to expand our PetMeds catalog with a broader set of consumable products and nutrition. PetCareRx&#8217;s catalog offerings include over 13,000 of the best non-medication health and wellness products, including food, supplements, and other similar products. They also bring us an incremental distribution center capability outside of our core medication distribution. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been rapidly filling in the strategic pieces of our strategy to take advantage of a growing industry, which is the topic of our next slide. As we have covered in our previous earnings calls, PetMeds operates in a growing addressable market. Because of our pending acquisition, partnerships, and core improvements in the PetMeds business, PetMeds is now able to actively participate in a broader addressable market across the pet wellness space. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our investments in vet care and a broader product selection, we are in an enviable position to gain market share and expand our relationship with our customers. Over time, we expect our revenues to be more diversified as we address a broader range of pet parents&#8217; needs. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is excited about how we have positioned PetMeds to be a growth company. The pet space has proven to be a resilient vertical, even in recessionary times. Pet parents see their pets as an extension of their own families and increasingly demand premium pet care options. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Here are some reasons why Management is excited about PetMeds&#8217; growth opportunities from a macro perspective&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Pet parents are less likely to reduce their pet purchasing budget, especially in the consumable and medication categories.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">U.S. household pet ownership has increased over time and today, 70% of U.S. households now own a pet. Those pet parents will need and seek health and wellness care provided by a trusted brand.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Consumers also now expect everything to be real-time, fast, and digital, a trend impacting every industry. The e-commerce channel continues to expand rapidly. We expect the pet vertical to follow this expansion, just like we have seen in other digital e-commerce verticals. Today, our addressable market is largely dominated by offline sales, but we see the growing trend to purchase online as an opportunity which will be very favorable for us.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">We also see a real trend towards the digitization of pet healthcare, just like we have in human health. Pet parents are thinking through the entire spectrum of their pet&#8217;s care, from diet to veterinary services, from infancy through old age, and they&#8217;re examining the channels through which they access those products and services. </font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe PetMeds is uniquely positioned to take advantage of these trends. By focusing on total wellness, we can offer products and services to pet parents that are diet- and health-focused in the areas of pet medication, premium prescription and non-prescription food, supplement, and televet services.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we dive into the quarterly financial results, I want to remind our stakeholders of several important achievements that signal the beginning of the transformation of PetMeds into a growth business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net new customer growth&#58; year-over-year customer growth shows the vitality of any growing business and we share good news on this front on today&#8217;s earnings call. As we expand our product catalog over the longer term, we anticipate that PetMed Express will benefit from having a higher LTV and more operating leverage to acquire customers at scale. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More subscription revenue&#58; we have seen substantial progress here and will continue to see more recurring business that enables PetMeds to be a more predictable business model, with higher LTV and increased loyalty.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sell more non-medication products&#58; the expansion of our product catalog and services has been a key initiative for us. We decided to turbo-charge this effort through the pending acquisition of PetCareRx. PetMeds will benefit by having more recurring sales, increased regular visits, thus delivering a higher LTV. Our customers desire a wider selection from us, and we look forward to working with the PetCareRx team once we close the transaction to work towards these expansion opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unique and differentiated services via digital-based healthcare services&#58; our goal is to continue to move more health and wellness services online, with our long-term perspective that this will be driven by pet medications and veterinary care. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next slide summarizes how these products and services are tied together.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PetMeds is uniquely positioned at the starting point with a highly regulated and complex pharmaceutical segment of the pet industry. Last month, we announced the agreement to acquire PetCareRx, a leading supplier of pet medications, premium food, and supplies. The combination of the two long-operating companies will greatly impact the longevity and happiness of pets on a larger scale. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PetCareRx has been operating as a privately owned pet health and wellness company for over 20 years. The acquisition is intended to provide the following advantages&#58; a greatly expanded addressable market beyond our current pet medication market&#59; immediate revenue and customer growth&#59; and greater non-medication sales for the core PetMeds business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are confident that we will see similar expansion of buying behavior with our PetMeds customers and will rapidly move the supplier relationships and products from the PetCareRx portfolio over to PetMeds over the next several quarters. Once the transaction closes, PetMeds will be working towards integrating the PetCareRx brands and catalog under the PetMeds e-commerce platform. Longer term, the win for pet parents and our stakeholders is that PetMeds will now be able to service a wider range of products and services, or what we like to refer to as &#8220;from nose to tail.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offering an expanded catalog to our recurring customers is a great place to start but that alone doesn&#8217;t create an adequate moat around the PetMeds business. As a result of consumer demand, we believe strongly that pet health services will become more digitally enabled, a trend that we have already seen in human health. We are very excited about our strategic relationship and minority ownership stake in Vester, our exclusive partner that accelerated our entry into the virtual telehealth and telemedicine space. </font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe pet telemedicine is going to be a huge trend over time, not unlike what we have seen with other services like online and mobile food and delivery services. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a slew of innovations that you can expect to see from PetMeds as we integrate the technology from our various partnerships in unique, differentiated and bespoke ways, and all of these efforts are designed to provide high efficacy outcomes for pets to live healthier and happier lives. Expect to see more innovations and product catalog extensions over the coming quarters that will deepen the benefit of our strategic pillars.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I would like to now turn the call over to Christine to walk you through our Q3 financial performance and the Company fundamentals. Christine&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Christine Chambers</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thank you, Matt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PetMeds has a strong set of core assets and capabilities, that we plan on leveraging to spur growth in the PetMeds business. PetMeds maintained a strong balance sheet of over $102 million of unrestricted cash as at December 31, 2022. Our brand is widely known and trusted. Our market research indicates that 55% of U.S. pet parents are aware of the PetMeds brand. Having a strong brand takes years to develop and our customers tell us they look at PetMeds as their trusted pharmacy and pet medication expert. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one of the largest direct-to-consumer vet networks in the online retail space, with over 70,000 veterinarians that we&#8217;ve worked with over the Company&#8217;s history. Because of our industry-leading service relationships with vets, our prescription medication authorization rates are the highest they&#8217;ve ever been, which speaks volumes to the level of veterinary cooperation that we receive on a daily basis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers love our brand and our service. Our NPS score is over 80, which puts us in the upper quartile, alongside some of the most beloved brands in the world. We provide a 100% satisfaction guarantee to our customers, and we go the extra mile with genuine, empathic, and expert service.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Matt previously mentioned, our AutoShip Program continues to grow and expand. Approximately 42% of our revenue was recurring revenue derived from our AutoShip Subscription Program during the third quarter. This is an 8% increase on a sequential basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I also want to say that I&#8217;m really excited with the speed at which we&#8217;ve begun to see business improvement. Investment in G&#38;A has provided greater transparency, smarter decision-making, and better analytics. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Let me turn to our financial results for the quarter ending December 31, 2022, our third fiscal quarter 2023. My remarks will compare this year&#8217;s quarterly results to the same quarter last year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third quarter revenue was $58.9 million compared to revenue of $60.7 million in the same period last year. While this is a decrease of 3%, there is an important milestone to highlight&#58; net new customer growth. We welcomed approximately 72,000 new pet parents this quarter, compared to 61,000 in the prior quarter and 66,000 in the prior year. This represents growth of over 9% year-over-year and an increase of 18% sequentially. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have actively targeted acquisition of lapsed customers through competitive promotions in the quarter to drive new customer acquisition. Repeat sales of $53 million for the quarter decreased 4% compared to repeat sales of $55 million in the same period last year.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit as a percentage of sales was 25.9% compared to 29.2% in the same quarter last year and 28.2% in the prior quarter. The decline in gross profit was primarily due to higher seasonal promotions during the quarter, as consistent throughout the industry. Our promotional activity, however, was specifically focused on reactivating our large base of lapsed customers. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With a more modern marketing stack and refreshed Marketing Team, we will lean into optimizing this customer base, and fully expect to cross-sell additional catalog to these customers in the future. While we&#8217;re always evaluating our promotional strategies, we don&#8217;t expect to repeat the deep promotions that we offered this past quarter to re-engage this specific customer set.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&#38;A increased $2.9 million year-over-year, but when normalized for non-operating costs relating to the pending PetCareRx transaction, G&#38;A increased $2.3 million year-over-year. This is due to an increase of $1.4 million related to payroll expenses, which includes $400,000 related to stock compensation, $500,000 related to the third-party resources, and some increases in software expenses in other G&#38;A. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exclusion of non-operating items, we do not expect G&#38;A to continue to increase at the same rate next fiscal year. We believe that the right team is largely in place now and that G&#38;A will be fairly flat exiting Fiscal Year 2023, and going forward. Please note, that as we push to close the acquisition in the fourth quarter, we will expect to see additional acquisition-related expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received and accrued for a sales tax assessment in the second quarter of Fiscal Year 2023. Based on the assessment received, the Company initiated a process to evaluate the potential for further sales tax contingencies. The result of this evaluation could have a material impact on the Company&#8217;s financial statements. We expect to complete the review in the quarter ending March 31, 2023, and we will provide a further update after we complete our full analysis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income was breakeven for the third quarter and zero cents per diluted share, and includes $500,000, or $0.02 per diluted share, for items not indicative of our ongoing operation. This is compared to $4.3 million or $0.21 per diluted share for the same quarter last year. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA for the quarter was $2.7 million compared to $7.6 million in the same quarter last year. The year-over-year decline reflects a decline in gross margin and targeted increases in G&#38;A. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we look forward, we&#8217;ll be primarily focused on closing and integrating the pending acquisition and driving returns on the recent investments. Management believes that the organic and inorganic investments that we&#8217;ve made over the last year in the business are sufficient to drive long-term sustainable growth going forward. Therefore, being focused on operating execution and integration is paramount in order to realize those future returns.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Now, I&#8217;d like to talk about the pending PetCareRx acquisition. We covered some of this material in our Analyst Day in January but we&#8217;d like to reiterate the structure and strategic rationale for the transaction&#58; total consideration of $36 million&#59; trailing 12-month revenue of $42 million&#59; 200,000 customers&#59; more than 10,000 brands and product SKUs&#59; around 80 employees and a headquarters and distribution center located in Long Island, New York&#59; and gross margins approximately the same as PetMeds. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned, we expect the deal to close this quarter. While the PetCareRx brand will continue to operate independently as part of the PetMeds wellness and consumables business, it&#8217;s expected to immediately deliver top line revenue growth. Over time, we expect it to be bottom line accretive as we leverage synergies and streamline infrastructure. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Now, I&#8217;d like to discuss our capital allocation. As we transform the PetMeds business, the acquisition of PetCareRx is the first catalyst that provides immediate growth as well as the ability to spend more in </font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variable marketing as we work to sell more products to our customer base. Over the long run, Management remains committed to driving total shareholder return. As such, for the third quarter, we will pay a dividend at the same rate as we have in prior quarters at $0.30 per share. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior practice, the Board will evaluate the declaration of dividends on a quarterly basis as part of our normal quarterly business cycle. In addition, Management strongly believes that investors will see a higher return over the long term through stock appreciation with a growing company in a growing market. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With that, I&#8217;ll turn the call back to Matt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thanks, Christine.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Again, Management is very encouraged by the performance of the business this quarter, as well as the impressive acceleration and the long-term business drivers. We announced today that PetMeds is poised for growth. As we have stated over the last several quarters, PetMeds is pursuing a vertical specialty retailer strategy. We aim to be pet parents&#8217; trusted pet health expert. We have been sharing our strategy with your for a little over a year and we have substantially filled in the pieces to build an enduring, profitable, and growing pet health company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be crystal clear on the measures for success&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net new customer growth. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">More subscription revenue. We have seen rapid progress here and will continue to see more recurring business that enables PetMeds to be a more predictable business model. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sell more non-medication products via product catalog expansion.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unique and differentiated services via digital-based healthcare services and veterinary care. We will continue to add more virtual care and wellness services that will contribute to greater loyalty or less customer churn.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Uniqueness in the market. With over 2 million unique customers, we are a well-known and trusted brand, and we operate in a market that is resilient to economic headwinds. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a strong balance sheet that provides us with the financial flexibility to take advantage of a large and growing market.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are excited to welcome our new pack (phon) members, PetCareRx. PetMeds&#8217; job is certainly not done. We will be working hard to integrate, execute, and go to market with these new assets and initiatives. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This ends our prepared remarks. Operator, we are now ready to take questions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operator&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thank you. Ladies and gentlemen, at this time, we will be conducting a question-and-answer session.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first question comes from the line of Erin Wright with Morgan Stanley. Please proceed with your question.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Erin Wright</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Great. Thanks for taking my questions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First, how should we be thinking about&#8212;and congrats on the new customer growth, but how should we be thinking about new customer growth in the coming quarters&#63; Do you think that we&#8217;ve hit an inflection point here&#63; Are there any other factors that we should be thinking about in terms of that quarterly progression&#63; Thanks.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thanks for the question, Erin. I&#8217;ll take that one. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes, we&#8217;re pretty excited that we saw net new customer growth for the first time in 2.5 years. A couple things are going on behind that number. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One is, one of the interesting things about PetMeds versus an early-stage business is that we&#8217;ve got a huge database of customers that up until recently we really didn&#8217;t have a lot to talk to about, so we&#8217;ve done a much better job of re-engaging lapsed customers. As you may recall, we changed the definition of our new customers to anyone that&#8217;s purchased with us in the last three years, and so we&#8217;re doing more specific targeted offers to our lapsed customer base, which we have found largely as being very CAC-efficient, customer acquisition-efficient. So that&#8217;s kind of one theme in the future, Erin, that you&#8217;ll see from us.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second theme is a little bit of what you heard around the thesis around PetCareRx and the expansion of our non-medication catalog. While CAC, overall, in our space has generally flattened in terms of trends, in terms of CAC trends, we do see an opportunity to increase lifetime value as we start selling more products to both the net new customers that we are bringing on, but also existing. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So I think the trends that you&#8217;ll see from us are probably less in terms of gross margin hit related to reigniting of lapsed customers but more focus on getting those customers to purchase more from us. So, on a go-forward basis, we are leaning more optimistic about our ability to grow our customer base. I hope that answered your question.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Erin Wright</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Great. Yes, no, thanks, that was great color. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Then, also, looking at just underlying demand trends across your customer base, whether it&#8217;s the dynamics around the upcoming flea and tick season, what you&#8217;re seeing in terms of consumer behavior around trade-down dynamics, what are you seeing in the sort of macro-environment just from an underlying demand perspective&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes, it&#8217;s a great question, Erin, and that&#8217;s such an important question for us. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As you know, we are a seasonally driven business, highly weighted towards the flea and tick season. I think this season is going to be very different than last season. I think last season was very abnormal on </font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">many different vectors. It was very unseasonably cold. We are looking very carefully at what we&#8217;re seeing in the vet channel, and also macro-economically with our supplier partners. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cautiously optimistic that the flea and tick season will be much better than it was last year. I think it would be very difficult to say it would be worse, but it&#8217;s too early to tell. I don&#8217;t think you&#8217;re going to see as cold as temperatures as we did last year, but we&#8217;re staying very attuned to all the macro data.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In terms of trade-downs, we are not seeing trade-down behavior in our business. As you know, we are very medication-focused and very prescription-focused in terms of the weighting in our business, and those customers, particularly diet- and health-focused customers, generally will stick with the brands that they love. Whether their favorite flea and tick brand or if it&#8217;s a skin brand, whatever it is, we don&#8217;t see consumers wanting to trade down, which is good news for us, and I would say that trend will likely continue. We&#8217;re relatively recessionary resilient. We haven&#8217;t seen a lot of trade-down behavior.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So, in terms of the macro, we&#8217;re going to stay very focused. Obviously, as we get into March, that&#8217;s when sales historically have increased for flea and tick, and we&#8217;ll be watching very carefully around seasonality, around temperatures. Did that answer your question, Erin&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Erin Wright</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes. Thank you so much. Appreciate it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thank you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operator</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next question comes from the line of Corey Grady with Jefferies. Please proceed with your question.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corey Grady</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hi, and thanks for taking my question. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I wanted to follow up on that and just talk about other factors that impact customer growth. We&#8217;ve seen vet industry visits down over the past year, and this is kind of a seasonally weak quarter for flea and tick. You added customers by activating lapsed customers. Maybe you can talk about what you&#8217;re seeing in the market in terms of customer intent and how you&#8217;re thinking about trends that might impact customer growth over the next year. Thanks.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It&#8217;s a great question. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In terms of the reignite of the existing lapsed customers, really that&#8217;s a new conversation. That&#8217;s why we changed the definition. We have a huge opportunity and what we&#8217;ve got is a lot of interesting net new data around what those customers want from a brand like PetMeds, and so it&#8217;s almost the way we think about it as having a completely new conversation. Some of those customers actually have a strong affinity obviously to the brand, but they haven&#8217;t really been introduced to us in a while, and so we&#8217;re treating them like they&#8217;re new customers because they are new customers.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those customers that are new seem to want a one-stop-shop, one place to get more of their products versus just one item. That could be&#8212;and this is speculation&#8212;related to inflationary concerns, it could be pre-recessionary concerns, but going to one place to get all of your needs is a developing theme, and we&#8217;ve seen this in other e-commerce retailers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In terms of the net new components to the strategy for both the existing customers as well as new, it&#8217;s hard to predict a customer acquisition trend, it&#8217;s a dynamic marketplace, but we&#8217;ve certainly seen those trends flatten in terms of increase in overall customer acquisition. Our customer acquisition costs on an absolute basis have been relatively flat, but we see a lot of interesting demand, which was the thesis for PetCareRx, to add more premium products like prescription food and premium food to the mix. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So, longer term, we see an opportunity to potentially lean into customer acquisition costs and expand our customers more rapidly, but, again, we are not in a position to comment on that yet. We haven&#8217;t closed PetCareRx, and we&#8217;ll focus very much on digesting the acquisition and working with that team and executing. Corey, did I answer your question&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corey Grady</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes, you did. That&#8217;s really helpful. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For my follow-up, I wanted to just get some more color on gross margin. You talked about going forward focusing less on promos and more on cross-selling. How should we think about gross margin for Q4 and into next year&#63; Thanks.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thanks, Corey. Christine, would you mind answering that question&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Christine Chambers</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes, thanks, Corey, for the question. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As I mentioned on the call, our gross margin in the quarter was really impacted by the targeted acquisition of those lapsed customers, and we really did lean into that with some of the sort of one-time promotions. That was an intentional move on our part to acquire those customers because of the opportunity that we see with cross-selling products and expanding the sort of portion of that customer&#8217;s basket going forward. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As I mentioned, there&#8217;s that, and also I would say that there was some&#8212;we often have co-op rebates that hit our cost of goods sold and those can vary from quarter to quarter. Now, both of those things negatively impacted gross margin this quarter, and we really don&#8217;t expect those to repeat to that extent going forward, and so we do expect to see our gross margin more in line with kind of the historic trends that we&#8217;ve seen in the past.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corey Grady</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Got it. Thank you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thanks, Corey.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operator</font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next question comes from the line of Anthony Lebiedzinski with Sidoti &#38; Company. Please proceed with your question.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anthony Lebiedzinski</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Good afternoon, and thank you for taking the questions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certainly nice to see new order sales growth in the quarter here. Your repeat sales or reorder sales were down about 4%. So, going forward, do you expect&#8212;obviously, your repeat sales drive around 90% of your total revenue, so how are you thinking about maintaining that repeat base of customers&#63; Do you expect to perhaps be more promotional to those customers, or how are you just broadly thinking about that and making sure that you&#8217;re at least able to maintain those repeat customers&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes. Anthony, thank you for that question. Christine, why don&#8217;t you answer the overall returning revenue trends and then I&#8217;ll follow up with maybe a strategy answer&#63;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Christine Chambers</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes, that sounds great. Hey, Anthony, great question. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we look at the returning customers, you&#8217;re right, we did see that 4% decline year-over-year. If you look at that contextually within the last six quarters, that&#8217;s the lowest decline that we&#8217;ve seen year-over-year than we&#8217;ve seen like I say over the last six quarters. So we really do see some of the trends starting to change there and actually starting to see less of a decline in that customer base. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Then, of course, as we&#8217;re thinking about the new customer acquisition and building sort of the top of the funnel, and then having the repeatability with our AutoShip Program as well as that expanded catalog, we really see that opportunity to drive greater stickiness.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I&#8217;ll hand back to Matt because I know he&#8217;ll have some additional comments here.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thanks, Christine. No, you actually added a couple elements that I was going to add. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthony, I would say that we don&#8217;t have a lot of shots on goal with our customers today, meaning primarily our customer engagement is over a year around prescription refills, and so that gives ample opportunity for customers to not engage with us and not have re-engagement and likely either go to another retailer or actually forget that they&#8217;re on some type of program with us, and so we&#8217;re looking to get more engagement with those customers through AutoShip, but also through selling more products. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We think selling more products and AutoShip is kind of a one-two-punch to answer that question because there is more competition in the market but also our customers want more products from us, and so we think the advent of those two things will really help bolster and stabilize the returning base over time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Then, as I&#8217;ve mentioned, more speculative investments that we&#8217;ve made on pet telemedicine I think are going to be really interesting to see how over the long term the regulatory environment changes but also how customers view PetMeds as not just a place to get your meds but it&#8217;s also a place to get all your other services that you&#8217;d expect to get. Our customers are very much aligned with how they think about </font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:justify"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their vet, which is why we really focus on pet telemedicine and connecting with vets through our VetLive service. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So over time, we think differentiation through services is going to be another ability for us to lower churn and provide a more meaningful experience for our customers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anthony Lebiedzinski</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Got it, yes. Thanks for that.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Then your advertising spending was up 7%. I was just wondering, are you seeing any changes in ad rates, given kind of where the economy is right now&#63; I just wanted to get your thoughts on that.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes, I&#8217;ll take that one, Christine. Anthony, good question. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes, when I say, &#8220;relatively flat,&#8221; obviously, there was a little bit of an increase. No, largely the fluctuations that we&#8217;ve seen are how we get incented from our supplier partners, which adds some variance, so we feel like overall, from what we see inside our marketing spend, that we&#8217;ve been relatively flat. There can be some variances based on the amount of discounts that flow through the P&#38;L from our supplier partners, but overall, when we look at the industry, whether it&#8217;s CPCs or CPMs, we&#8217;re not seeing a lot of fluctuation in price right now. That can change, and it has changed significantly quarter-over-quarter, based usually on the macro-environment, but it has somewhat stabilized in terms of our customer acquisition costs and we&#8217;re not super-concerned about that.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anthony Lebiedzinski</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Got it. Okay, well, thank you, and best of luck.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thanks, Anthony, for your questions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operator</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no further questions in the queue. I&#8217;d like to hand the call back to Management for closing remarks.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matt Hulett</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thank you for joining our call today. I&#8217;m confident that the future we envision for PetMeds, along with the foundation that we&#8217;ve been laying, will meet the market opportunity in unique and innovative ways and will lead to improved operating results and increased shareholder value. PetMeds&#8217; brand, expertise, and reputation are unparalleled. We have greatly accelerated our operating roadmap and we look forward to sharing our progress in positively changing the lives of our pet parents and pets. Thank you for your continued support.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operator</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ladies and gentlemen, this does conclude today&#8217;s teleconference. Thank you for your participation. You may disconnect your lines at this time. Have a wonderful day.</font></div><div style="height:97.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pets-20230206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f71bd024-2379-44df-bea2-c74ac69705bb,g:b581da7e-e97f-40a0-a46a-3202eaa8a288-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pets="http://www.1800petmeds.com/20230206" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.1800petmeds.com/20230206">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20230206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pets-20230206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.1800petmeds.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>pets-20230206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f71bd024-2379-44df-bea2-c74ac69705bb,g:b581da7e-e97f-40a0-a46a-3202eaa8a288-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_5ebcb52c-bc51-4806-aa73-813409aa0f96_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8a4a80ef-19bf-4e2c-a332-a0fd98ef8b45_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2c837cdf-b2ab-42a3-be18-586d0478f0f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c8f44f93-a8b9-4b34-8743-61eed941befa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3f9cbe9e-50d2-4fb1-97fd-f318da9c9c2f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_406b7561-482a-443d-b92c-02b79155cc64_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1614e3fc-c8c7-426a-b419-856f0d3b0e47_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ce93bfb9-07c8-4d5f-8658-580c4f0e238b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a5be356b-d94d-4ff4-b6e0-4d416ddc3820_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9b3fe98d-a5f7-44d5-9087-b6d6d0e2c7d5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6e9192c2-da22-4cc8-b5c3-7da67d7c536a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_ab70a55e-9927-4eea-a1d8-bc8e8d029bb4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c00ec3e0-fd22-4023-8f04-5a884110f202_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_33eb9b12-7e31-4981-871a-f969cdef40ad_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7cd10621-0e9b-4fa7-910d-8dbcd944bc22_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_833c3a1e-cf8e-43d2-88e9-523c15ccfa85_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_51fd4e7a-64de-4482-ba32-d670680989ad_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e6dc109c-7601-4ba2-bc20-7f64dab3f3aa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_03283eaf-2dff-48f5-83c9-b0bf5f1e5b59_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_398c7eab-9e5c-496c-afde-443b07fdd2ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_db256229-8892-4034-8f9e-00ef09574161_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_61e06b6d-0cf0-4db8-8e5d-5a25f14ccf05_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>pets-20230206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f71bd024-2379-44df-bea2-c74ac69705bb,g:b581da7e-e97f-40a0-a46a-3202eaa8a288-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.1800petmeds.com/role/Cover" xlink:type="simple" xlink:href="pets-20230206.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.1800petmeds.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_024974f3-11fe-4c82-94e7-76ff093ef685" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_DocumentType_024974f3-11fe-4c82-94e7-76ff093ef685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7bb8f820-c16c-486e-9a84-66083256c2c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_DocumentPeriodEndDate_7bb8f820-c16c-486e-9a84-66083256c2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dc48420a-111b-44dd-971f-c97d4333a175" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityRegistrantName_dc48420a-111b-44dd-971f-c97d4333a175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bbfd7499-e328-4520-8a37-384aba46e122" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bbfd7499-e328-4520-8a37-384aba46e122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f7c0c7d6-975c-4b31-860e-c4cd8637733a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityFileNumber_f7c0c7d6-975c-4b31-860e-c4cd8637733a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c275dd83-8338-49a2-9ce7-f19763dddc5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityTaxIdentificationNumber_c275dd83-8338-49a2-9ce7-f19763dddc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_31fb63ac-0d31-4ddd-b0a1-1be5cd46932e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityAddressAddressLine1_31fb63ac-0d31-4ddd-b0a1-1be5cd46932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_747fac00-ddd1-4015-bb49-a5853b8bcdd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityAddressCityOrTown_747fac00-ddd1-4015-bb49-a5853b8bcdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_644b2a05-d4ef-46be-bec6-4013ff301022" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityAddressStateOrProvince_644b2a05-d4ef-46be-bec6-4013ff301022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e2fe8db3-5e3c-4388-b9e4-f9800777394d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityAddressPostalZipCode_e2fe8db3-5e3c-4388-b9e4-f9800777394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7e8bcdc2-c88d-4631-a843-d056ed80cb04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_CityAreaCode_7e8bcdc2-c88d-4631-a843-d056ed80cb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2288ae37-201d-49e0-84f1-38eeece0e911" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_LocalPhoneNumber_2288ae37-201d-49e0-84f1-38eeece0e911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_15205433-2c2c-44ad-90ae-6f959a4b7027" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_WrittenCommunications_15205433-2c2c-44ad-90ae-6f959a4b7027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_04df217a-0a0d-4056-a7ac-97b25336a32b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_SolicitingMaterial_04df217a-0a0d-4056-a7ac-97b25336a32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_bcf864a1-ed29-43c9-96f8-cbfc71762bee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_PreCommencementTenderOffer_bcf864a1-ed29-43c9-96f8-cbfc71762bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_85e36440-46bd-49aa-bace-49463fd49277" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_85e36440-46bd-49aa-bace-49463fd49277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d7252d32-a65a-4e12-842d-75f0cffe63d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_Security12bTitle_d7252d32-a65a-4e12-842d-75f0cffe63d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b8d8df0b-5d68-497e-932b-50e3105fdcf6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_TradingSymbol_b8d8df0b-5d68-497e-932b-50e3105fdcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bf365cb3-847b-4dfb-9602-2cd08db325d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityEmergingGrowthCompany_bf365cb3-847b-4dfb-9602-2cd08db325d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0fc60522-0df8-4a7b-a327-f75f6fc48b02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_EntityCentralIndexKey_0fc60522-0df8-4a7b-a327-f75f6fc48b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ff99e5b3-80ab-44cf-a6fa-6987fd3f73d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_AmendmentFlag_ff99e5b3-80ab-44cf-a6fa-6987fd3f73d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_da567a70-6f0e-42aa-aa1b-1b764aba79e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_749138ff-e74c-4bf2-ac13-749af8ef8581" xlink:to="loc_dei_SecurityExchangeName_da567a70-6f0e-42aa-aa1b-1b764aba79e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140397545517968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  06,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PetMed Express, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-28827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0680967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">420 South Congress Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Delray Beach<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">526-4444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PETS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001040130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>pets-20230206_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pets-20230206.xsd" xlink:type="simple"/>
    <context id="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001040130</identifier>
        </entity>
        <period>
            <startDate>2023-01-13</startDate>
            <endDate>2023-01-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M180L2ZyYWc6M2ZiMjMxZTUwMzI2NDMxMzkyNWFjNGQ1YjY3ZDhmZDUvdGFibGU6MmI4ZmNlMjYzOTIxNDUwY2JjMDI0NzFiMjk5YjFjNzkvdGFibGVyYW5nZToyYjhmY2UyNjM5MjE0NTBjYmMwMjQ3MWIyOTliMWM3OV8xLTEtMS0xLTI0NjQw_3f88cd89-6b0e-4a79-a891-23f0811012bc">0001040130</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M180L2ZyYWc6M2ZiMjMxZTUwMzI2NDMxMzkyNWFjNGQ1YjY3ZDhmZDUvdGFibGU6MmI4ZmNlMjYzOTIxNDUwY2JjMDI0NzFiMjk5YjFjNzkvdGFibGVyYW5nZToyYjhmY2UyNjM5MjE0NTBjYmMwMjQ3MWIyOTliMWM3OV8yLTEtMS0xLTI0NjQw_3a5d8b54-b2b2-4b4a-a87e-8ca6d783ae7a">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzY5_b6d8efd9-0e66-4f33-b77e-48a723d33cd8">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzcw_5c83e5fe-2843-4d59-ad80-33e92443bbac">2023-02-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzY2_bebc7565-abc5-4463-9def-94d0ab7d0df8">PetMed Express, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6YjQ1NTdlOGU4OTc0NDgxMGE5Y2JlZTU5YmQzNTEwNTQvdGFibGVyYW5nZTpiNDU1N2U4ZTg5NzQ0ODEwYTljYmVlNTliZDM1MTA1NF8wLTAtMS0xLTI0NjQw_0a5c9bcb-75e7-47a7-8b9c-912f16ddffc1">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6YjQ1NTdlOGU4OTc0NDgxMGE5Y2JlZTU5YmQzNTEwNTQvdGFibGVyYW5nZTpiNDU1N2U4ZTg5NzQ0ODEwYTljYmVlNTliZDM1MTA1NF8wLTItMS0xLTI0NjQw_66e74876-cd15-496f-b8e1-7f58bdf30b69">000-28827</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6YjQ1NTdlOGU4OTc0NDgxMGE5Y2JlZTU5YmQzNTEwNTQvdGFibGVyYW5nZTpiNDU1N2U4ZTg5NzQ0ODEwYTljYmVlNTliZDM1MTA1NF8wLTQtMS0xLTI0NjQw_d008f019-6ac7-4bf7-b250-f39b175fad40">65-0680967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzYx_431e0d2e-3d83-40d8-b2b3-e380e1043410">420 South Congress Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzcx_9a21f683-8e90-4885-be29-a872f7716162">Delray Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzYy_84bc0e09-defb-4f5d-a223-36ad1f4540cd">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzY4_4490f66c-c6c6-4cd1-bb70-84c76c80f2d9">33445</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV80Mjc_b969d61d-a84c-4be6-944c-b71ca8e54c44">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzYz_27a45da4-004d-48ef-a6e7-66ea17d1fcb2">526-4444</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6NjVmMjA0MDM4MWY2NGI2MWFkZmJmNWMzYjlhMDk4NGIvdGFibGVyYW5nZTo2NWYyMDQwMzgxZjY0YjYxYWRmYmY1YzNiOWEwOTg0Yl8wLTAtMS0xLTI0NjQw_8b25a460-b9a5-4947-bce9-7552e3b3973d">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6NjVmMjA0MDM4MWY2NGI2MWFkZmJmNWMzYjlhMDk4NGIvdGFibGVyYW5nZTo2NWYyMDQwMzgxZjY0YjYxYWRmYmY1YzNiOWEwOTg0Yl8yLTAtMS0xLTI0NjQw_66b2c027-3cd3-4c39-ba4c-88caac8551b1">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6NjVmMjA0MDM4MWY2NGI2MWFkZmJmNWMzYjlhMDk4NGIvdGFibGVyYW5nZTo2NWYyMDQwMzgxZjY0YjYxYWRmYmY1YzNiOWEwOTg0Yl80LTAtMS0xLTI0NjQw_89fa5783-bea3-45cc-8fd4-a7eb2dab08e2">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6NjVmMjA0MDM4MWY2NGI2MWFkZmJmNWMzYjlhMDk4NGIvdGFibGVyYW5nZTo2NWYyMDQwMzgxZjY0YjYxYWRmYmY1YzNiOWEwOTg0Yl82LTAtMS0xLTI0NjQw_181bdc72-68a4-40c7-8fa2-91a48c18264f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6MDc1YzA3ZTEyMDdmNDRjZWI1NTkyN2QwZDk5N2RlMjUvdGFibGVyYW5nZTowNzVjMDdlMTIwN2Y0NGNlYjU1OTI3ZDBkOTk3ZGUyNV8xLTAtMS0xLTI0NjQw_fac3bb8c-22e5-4f2c-b238-40390331d47b">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6MDc1YzA3ZTEyMDdmNDRjZWI1NTkyN2QwZDk5N2RlMjUvdGFibGVyYW5nZTowNzVjMDdlMTIwN2Y0NGNlYjU1OTI3ZDBkOTk3ZGUyNV8xLTEtMS0xLTI0NjQw_1aff08d7-29ac-4090-9d43-2eb3cc74b908">PETS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGFibGU6MDc1YzA3ZTEyMDdmNDRjZWI1NTkyN2QwZDk5N2RlMjUvdGFibGVyYW5nZTowNzVjMDdlMTIwN2Y0NGNlYjU1OTI3ZDBkOTk3ZGUyNV8xLTItMS0xLTI0NjQw_86d15b6f-bf00-432a-9950-38450a6829e6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyZjZkOGZkN2U5MjRlMGFiMGIwNjMwM2VjZDljNzYzL3NlYzpkMmY2ZDhmZDdlOTI0ZTBhYjBiMDYzMDNlY2Q5Yzc2M18xL2ZyYWc6Y2IwZTQ4YTFkMjVjNDAzMmI5NzAwMGZhMjM5MzhhMDEvdGV4dHJlZ2lvbjpjYjBlNDhhMWQyNWM0MDMyYjk3MDAwZmEyMzkzOGEwMV8xMzY0_0ffec528-21ba-4e92-bfc1-ed77f5e0cdd2">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M"_A\J93Y:-BS:_G3P^@_4$L#!!0    ( "B/1U:?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
M*(]'5JK$(A8S 0  (@(   \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J
M'[ 6M"$-45Y VY"F#8V)]]"ZU"*)*\>%C:^?VZH:TE[VE-S9NMQ=%A?BTX'H
ME'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8
MM;:<W@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(
M\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#
M+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U
M!D.LL8DF"=9#;E9T!N[RZ .;<L@F:NJF*9ZC#GA3#O9&3R54&*!\4YFHO/93
M;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    ( "B/1U8D'INB
MK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,
MA:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@
MMO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<
M//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P
M6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  HCT=6
M99!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\2
M95LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&P
MZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5
M,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0
MBJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*I
ML0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U
M[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_
M 5!+ 0(4 Q0    ( "B/1U8'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ *(]'5L1=&U+N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ *(]'5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  HCT=61.SV)T<$  "&$   &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ *(]'5I^@&_"Q @  X@P   T              ( !B@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  HCT=6EXJ[',     3 @  "P
M@ %F#P  7W)E;',O+G)E;'-02P$"% ,4    "  HCT=6JL0B%C,!   B @
M#P              @ %/$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M*(]'5B0>FZ*M    ^ $  !H              ( !KQ$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ *(]'5F60>9(9 0  SP,  !,
M             ( !E!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  WA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pets-20230206.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.1800petmeds.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="pets-20230206.htm">pets-20230206.htm</File>
    <File>ex991-earningsconferenceca.htm</File>
    <File>pets-20230206.xsd</File>
    <File>pets-20230206_lab.xml</File>
    <File>pets-20230206_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pets-20230206.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "pets-20230206.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pets-20230206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pets-20230206_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pets-20230206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "pets",
   "nsuri": "http://www.1800petmeds.com/20230206",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pets-20230206.htm",
      "contextRef": "i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.1800petmeds.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pets-20230206.htm",
      "contextRef": "i992cd1fc3c5647a6a1110616a0e9153c_D20230113-20230113",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.1800petmeds.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001040130-23-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001040130-23-000015-xbrl.zip
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M[_)3M4-4C&,4',>X=+&RT$!+#N\DHW?6>W-WV50VPU;T3S,<2+JH*Q^[[<B
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M[]DV7H6+QR;U%E7:PE.INH9F67.B,.U,JW@C2T4Y>$\]58*EY7OR !E:58Q
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M#TE77GEF=X]#,T]0CAT-$FBX > AH=OMFUIL@$7(,4]JHP:<F6 0])7NI_Z
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MX\&"$ _<IGMN1 4]56:'\=$T-(1!N#-.&3(,GSSYVR?LR?,H1G>N7(24I;0
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ML655%-4.J!'KC(KYX"!_Q,UY!%FGM-M'&I(%V B;JY=L;DF3E.02F(>&+>O
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MB*#.G=2<D)"_&]L*C_=<M]R0/[5A+O= IJ/S@T9*IRH'J+ ]),NNYK/*+V(
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M=O5K]XOT%VSW_6()O6"WV8O!'U!+ P04    "  ICT=6N>U[OD0*   870
M%0   '!E=',M,C R,S R,#9?;&%B+GAM;-5<76_;.A)][Z_09E]V@;*F)$HB
MBS87W=QV46QN6S0I>K&+A<'/1*@M!;+2)/]^*=E.+)NR12I6M2^)8X^&9XYY
MAJ.AF#>_W<]GWD]9+-(\>WOBOX(GGLQX+M+LZNW)M\L/ )_\=OKBQ9N_ /#G
M/[Z>>[_G_'8NL]([*R0MI?#NTO+:^R[DXH>GBGSN?<^+'^E/"L!I?=%9?O-0
MI%?7I1? (-S^M'BM$I\)&" 0A D!" D%F*0!X FB/"8)C!A[>?6:1=@7-)%
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M$:^$]=(HFCOWX^K Y3H+5@$!HR(1U%)BA;2$XU7!6FV9UOU%RZ+Z>-"].-O
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M2P$"% ,4    "  ICT=6P%=L+MTZ  !#2 $ '@              @ $
M97@Y.3$M96%R;FEN9W-C;VYF97)E;F-E8V$N:'1M4$L! A0#%     @ *8]'
M5I.T=YI4&   _)8  !$              ( !&3L  '!E=',M,C R,S R,#8N
M:'1M4$L! A0#%     @ *8]'5OY.):%J @  =P<  !$              ( !
MG%,  '!E=',M,C R,S R,#8N>'-D4$L! A0#%     @ *8]'5KGM>[Y$"@
M&%T  !4              ( !-58  '!E=',M,C R,S R,#9?;&%B+GAM;%!+
M 0(4 Q0    ( "F/1U90[*"SJ08  .(P   5              "  :Q@  !P
J971S+3(P,C,P,C V7W!R92YX;6Q02P4&      4 !0!0 0  B&<

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
